About: Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge
Creator	Corrêa-Oliveira, Rodrigo Gama-Ker, Henrique Aguiar-Soares, Oliveira Assis Martins-Filho, Olindo Dian, Rodrigo Gontijo, Nelder Mendes Roatt, Bruno Reis, Alexandre Alves, Rodrigues Araújo, Silva Cordeiro Giunchetti, Rodolfo Da Silveira-Lemos, Denise Fujiwara, Ricardo Luiza, Marina Resende, Lucilene Sobreira, Márcio Zanandreis De Mendonça, Ludmila
source	Medline; PMC
abstract	Dogs represent the most important domestic reservoir of L. chagasi (syn. L. infantum). A vaccine against canine visceral leishmaniasis (CVL) would be an important tool for decreasing the anxiety related to possible L. chagasi infection and for controlling human visceral leishmaniasis (VL). Because the sand fly salivary proteins are potent immunogens obligatorily co-deposited during transmission of Leishmania parasites, their inclusion in an anti-Leishmania vaccine has been investigated in past decades. We investigated the immunogenicity of the “LbSapSal” vaccine (L. braziliensis antigens, saponin as adjuvant, and Lutzomyia longipalpis salivary gland extract) in dogs at baseline (T(0)), during the post-vaccination protocol (T(3rd)) and after early (T(90)) and late (T(885)) times following L. chagasi-challenge. Our major data indicated that immunization with “LbSapSal” is able to induce biomarkers characterized by enhanced amounts of type I (tumor necrosis factor [TNF]-α, interleukin [IL]-12, interferon [IFN]-γ) cytokines and reduction in type II cytokines (IL-4 and TGF-β), even after experimental challenge. The establishment of a prominent pro-inflammatory immune response after “LbSapSal” immunization supported the increased levels of nitric oxide production, favoring a reduction in spleen parasitism (78.9%) and indicating long-lasting protection against L. chagasi infection. In conclusion, these results confirmed the hypothesis that the “LbSapSal” vaccination is a potential tool to control the Leishmania chagasi infection.
has issue date	2016-08-24(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0161169
bibo:pmid	27556586
has license	cc-by
sha1sum (hex)	60f0773c8eeace01dd0364c5c63febbfe9dd3a62
schema:url	https://doi.org/10.1371/journal.pone.0161169
resource representing a document's title	Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge
has PubMed Central identifier	PMC4996460
has PubMed identifier	27556586
schema:publication	PLoS One
resource representing a document's body	covid:60f0773c8eeace01dd0364c5c63febbfe9dd3a62#body_text
is schema:about of	named entity 'IMMUNOLOGICAL' named entity 'extract' named entity 'infection' named entity 'type II' named entity 'protocol' named entity 'immunization' named entity 'Immunological' named entity 'Canine' named entity 'VACCINE' named entity 'LEISHMANIA CHAGASI' named entity 'VACCINATION PROTOCOL' named entity 'SALIVARY GLAND' named entity 'PARASITES' named entity 'OUR' named entity 'AND LATE' named entity 'RELATED' named entity 'IMMUNOGENICITY' named entity 'ESTABLISHMENT' named entity 'EXPERIMENTAL' named entity 'RESERVOIR' named entity 'REDUCTION' named entity 'CONFIRMED' named entity 'PARASITISM' named entity 'ENHANCED' named entity 'TYPE I' named entity 'LEISHMANIA' named entity 'DOMESTIC' named entity 'HUMAN' named entity 'CANINE VISCERAL LEISHMANIASIS' named entity 'SAPONIN' named entity 'TIMES' named entity 'NITRIC OXIDE PRODUCTION' named entity 'LEISHMANIA VACCINE' named entity 'NECROSIS FACTOR' named entity 'LUTZOMYIA LONGIPALPIS' named entity 'INDICATED' named entity 'RESULTS' named entity 'VACCINE' named entity 'EARLY' named entity 'SALIVARY PROTEINS' named entity 'PARASITOLOGICAL' named entity 'CHALLENGE' named entity 'AMOUNTS' named entity 'VISCERAL LEISHMANIASIS' named entity 'MAJOR' named entity 'PROMINENT' named entity 'BASELINE' named entity 'DOGS' named entity 'LEVELS' named entity 'INVESTIGATED' named entity 'CYTOKINES' named entity 'IMMUNE RESPONSE' named entity 'TOOL' named entity 'PRO-' named entity 'CANINE' named entity 'IMPACT' named entity 'REPRESENT' named entity 'BIOMARKERS' named entity 'LEISHMANIA CHAGASI' named entity 'INFLAMMATORY' named entity 'ANTIGENS' named entity 'IMMUNIZATION' named entity 'CONTROLLING' named entity 'L. INFANTUM' named entity 'LONG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software